BB Biotech (BION) AI Stock Analysis

• Market Cap: CHF2.66B
• Dividend Yield: 3.95%
• Average Volume (3M): 98.23K
• Price to Earnings (P/E): 16.1
• Beta (1Y): 0.97
• Revenue Growth: 83.74%
• EPS Growth: 31.82%
• Country: CH
• Employees: 10
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 8.16
• Shares Outstanding: 55,400,000
• 10 Day Avg. Volume: 119,513
• 30 Day Avg. Volume: 98,228
• PEG Ratio: -0.19
• Price to Book (P/B): 0.85
• Price to Sales (P/S): 17.44
• P/FCF Ratio: 6.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF66.00
• Price Target Upside: 36.08% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 68 Neutral
• Price Target: CHF49.00 ▲(1.03% Upside)

The score is driven primarily by improved 2024 financial performance (profitability, cash flow, and low leverage) but tempered by pronounced historical volatility. Technicals add support via an uptrend and positive MACD, while valuation is reasonable with a ~3.95% dividend yield.

BB Biotech Business Overview & Revenue Model

Company Description

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.

How the Company Makes Money

BB Biotech makes money through its investment activities in the biotechnology sector. The company generates revenue primarily from the appreciation of its investments in biotechnology companies. This includes capital gains realized from selling shares of companies within its portfolio at a profit. BB Biotech also earns income from dividends distributed by the companies in which it holds equity. The company's success is closely tied to the performance of its portfolio companies, which can be influenced by factors such as successful clinical trial results, regulatory approvals, and market demand for new therapies. Additionally, BB Biotech may engage in strategic partnerships or collaborations to enhance its investment opportunities and returns.

BB Biotech Financial Statement Overview

Summary

BB Biotech demonstrates a strong recovery in profitability with a net profit margin of 68% and low debt, indicating financial stability. However, historical volatility in revenue and cash flow is a risk that needs to be managed to ensure continued growth.

Income Statement

The income statement shows a significant recovery in the latest period with a total revenue of $111.63 million and net income of $75.9 million, reflecting a positive turnaround from negative figures in prior years. Gross profit margin is 100%, and net profit margin is approximately 68%, both indicating strong profitability. However, the company has experienced volatility in revenue growth, with a dramatic shift from negative to positive, which may pose risks if not stabilized.

Balance Sheet

The balance sheet is strong, with high stockholders' equity of $2.29 billion and low total debt of $117.5 million, resulting in a low debt-to-equity ratio of approximately 0.05, indicating financial stability. The equity ratio stands at approximately 95%, highlighting a robust capital structure with substantial equity backing. While liabilities are minimal, the trajectory of total assets declining requires monitoring.

Cash Flow

The cash flow statement reflects healthy operating cash flow of $304.56 million, showing improvement and a solid free cash flow. The operating cash flow to net income ratio is strong, indicating efficient cash generation. However, historical fluctuations in cash flow performance suggest potential volatility, which could impact future liquidity and investment capacity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-176.15M	111.63M	35.00K	4.00K	-396.22M	699.23M
Gross Profit	-176.15M	111.63M	35.00K	4.00K	-396.22M	699.23M
EBITDA	0.00	80.24M	-201.26M	-357.29M	-402.79M	691.25M
Net Income	-438.69M	75.90M	-206.61M	-357.81M	-404.81M	691.17M
Balance Sheet
Total Assets	1.84B	2.41B	2.64B	3.05B	3.64B	3.96B
Cash, Cash Equivalents and Short-Term Investments	2.16M	2.41B	2.64B	3.05B	3.64B	3.96B
Total Debt	0.00	117.50M	304.90M	363.00M	355.00M	63.00M
Total Liabilities	2.43M	121.11M	313.94M	367.25M	355.00M	63.00M
Stockholders Equity	1.84B	2.29B	2.32B	2.69B	3.28B	3.89B
Cash Flow
Free Cash Flow	435.73M	304.56M	218.28M	-357.81M	-94.79M	262.45M
Operating Cash Flow	435.73M	304.56M	218.28M	-357.81M	-94.79M	262.45M
Investing Cash Flow	0.00	0.00	0.00	588.94M	0.00	0.00
Financing Cash Flow	-427.20M	-305.20M	-220.21M	-233.27M	91.77M	-284.48M

BB Biotech Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 48.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BION, the sentiment is Positive. The current price of 48.5 is above the 20-day moving average (MA) of 45.86, above the 50-day MA of 44.07, and above the 200-day MA of 35.11, indicating a bullish trend. The MACD of 1.01 indicates Negative momentum. The RSI at 67.87 is Neutral, neither overbought nor oversold. The STOCH value of 94.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:BION.

BB Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSLN	73 Outperform	CHF689.45M	9.47	―	―	58.51%	―
BION	68 Neutral	CHF2.66B	16.10	-20.74%	3.95%	83.74%	31.82%
NWRN	67 Neutral	$535.39M	22.33	―	―	744.64%	―
KURN	61 Neutral	CHF1.06B	-167.65	-7.82%	―	104.01%	33.25%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MOLN	48 Neutral	CHF134.45M	-2.05	-49.86%	―	-100.00%	14.45%
IDIA	46 Neutral	CHF952.55M	-5.71	―	―	229.23%	63.47%

BB Biotech Corporate Events

BB Biotech AG Reports Strong Profit Growth in 2025 Interim Report

BB Biotech AG has released its interim report for the first nine months of 2025, revealing a significant profit increase to CHF 106 million, compared to CHF 16 million in the same period last year. The third quarter alone saw a profit of CHF 448 million, a notable turnaround from a loss of CHF 157 million in the previous year, reflecting positive share price developments in its portfolio companies.

The most recent analyst rating on (CH:BION) stock is a Buy with a CHF66.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.

BB Biotech’s Q3 2025 Performance Surpasses Expectations Amid Industry Recovery

BB Biotech AG reported strong financial performance in Q3 2025, with its portfolio exceeding the Nasdaq Biotech Index benchmark. The company’s stock price and net asset value showed significant growth, driven by a revitalized biotech industry and increased M&A activity. The US Federal Reserve’s interest rate cut and easing inflation contributed to improved market conditions, enhancing investor confidence. BB Biotech’s strategic focus on RNA-based therapeutics and mid-cap innovators, along with its inclusion in the SPI ESG Index, underscores its commitment to sustainable and responsible investing. The company is well-positioned for future growth, supported by a solid liquidity base and advancements in AI-driven research.

The most recent analyst rating on (CH:BION) stock is a Buy with a CHF66.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.